165 related articles for article (PubMed ID: 17180728)
1. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.
Obradovic T; Dobson GG; Shingaki T; Kungu T; Hidalgo IJ
Pharm Res; 2007 Feb; 24(2):318-27. PubMed ID: 17180728
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs.
Neuhaus W; Mandikova J; Pawlowitsch R; Linz B; Bennani-Baiti B; Lauer R; Lachmann B; Noe CR
Pharmazie; 2012 May; 67(5):432-9. PubMed ID: 22764578
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Salisbury JA; Tippin TK; Serabjit-Singh CJ
J Pharm Sci; 2003 Oct; 92(10):2082-9. PubMed ID: 14502547
[TBL] [Abstract][Full Text] [Related]
4. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines.
Chishty M; Reichel A; Siva J; Abbott NJ; Begley DJ
J Drug Target; 2001 Jun; 9(3):223-8. PubMed ID: 11697207
[TBL] [Abstract][Full Text] [Related]
5. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
Mahar Doan KM; Wring SA; Shampine LJ; Jordan KH; Bishop JP; Kratz J; Yang E; Serabjit-Singh CJ; Adkison KK; Polli JW
Pharmacology; 2004 Oct; 72(2):92-8. PubMed ID: 15331914
[TBL] [Abstract][Full Text] [Related]
6. Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Yu XQ; Chowbay B; Wen JY; Duan W; Chan E; Li XT; Cao J; Li CG; Xue CC; Zhou SF
Pharm Res; 2007 Sep; 24(9):1668-90. PubMed ID: 17551811
[TBL] [Abstract][Full Text] [Related]
7. Why are second-generation H1-antihistamines minimally sedating?
Hu Y; Sieck DE; Hsu WH
Eur J Pharmacol; 2015 Oct; 765():100-6. PubMed ID: 26291661
[TBL] [Abstract][Full Text] [Related]
8. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
[TBL] [Abstract][Full Text] [Related]
9. The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers.
Crowe A; Wright C
Xenobiotica; 2012 Jun; 42(6):538-49. PubMed ID: 22188412
[TBL] [Abstract][Full Text] [Related]
10. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic overview of oral second-generation H1 antihistamines.
González MA; Estes KS
Int J Clin Pharmacol Ther; 1998 May; 36(5):292-300. PubMed ID: 9629995
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier.
Chen X; Zhou ZW; Xue CC; Li XX; Zhou SF
Xenobiotica; 2007 Jun; 37(6):635-78. PubMed ID: 17614009
[TBL] [Abstract][Full Text] [Related]
13. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
14. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates.
Warren KE; Patel MC; McCully CM; Montuenga LM; Balis FM
Cancer Chemother Pharmacol; 2000; 45(3):207-12. PubMed ID: 10663638
[TBL] [Abstract][Full Text] [Related]
15. Identification of P-glycoprotein co-fractionating proteins and specific binding partners in rat brain microvessels.
Tome ME; Schaefer CP; Jacobs LM; Zhang Y; Herndon JM; Matty FO; Davis TP
J Neurochem; 2015 Jul; 134(2):200-10. PubMed ID: 25832806
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
17. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ.
Rice A; Liu Y; Michaelis ML; Himes RH; Georg GI; Audus KL
J Med Chem; 2005 Feb; 48(3):832-8. PubMed ID: 15689167
[TBL] [Abstract][Full Text] [Related]
18. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
Peng SX; Ritchie DM; Cousineau M; Danser E; Dewire R; Floden J
J Pharm Sci; 2006 Sep; 95(9):1984-93. PubMed ID: 16850393
[TBL] [Abstract][Full Text] [Related]
19. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines.
Ambroziak K; Kuteykin-Teplyakov K; Luna-Tórtos C; Al-Falah M; Fedrowitz M; Löscher W
Eur J Pharmacol; 2010 Feb; 628(1-3):57-66. PubMed ID: 19958760
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain.
Karssen AM; Meijer OC; van der Sandt IC; Lucassen PJ; de Lange EC; de Boer AG; de Kloet ER
Endocrinology; 2001 Jun; 142(6):2686-94. PubMed ID: 11356720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
